| Bioactivity | Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC50=2.60 μM)[1]. |
| Formula | C23H23F3N6O2 |
| Molar Mass | 472.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yao Cheng, et al. "Design, synthesis and biological evaluation of glucose metabolism inhibitors as anticancer agents." Bioorganic Chemistry (2024): 107665. |